PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

about

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

Item

http://www.wikidata.org/entity/Q48037303

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

@en

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

@nl

type

Item

label

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

@en

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

@nl

prefLabel

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

@en

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.

@nl

P1476

PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS

@en

P2093

Leonidas C Platanias

http://www.w3.org/2001/XMLSchema#string

P2860

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Clinical effect of point mutations in myelodysplastic syndromes

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

Risks of myeloid malignancies in patients with autoimmune conditions.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.

Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.

P304

764-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2016.1251594

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sameem Abedin

P577

2016-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27808592

http://www.w3.org/2001/XMLSchema#string